First patient dosed in MacroGenics’ Phase I MGC030 trial
US-based clinical-stage biopharmaceutical company MacroGenics has dosed the first patient in a Phase I study of its investigational therapy, MGC030,…
News
Merz concludes enrolment in Phase III Xeomin trials for migraine
Verastem’s KRAS inhibitor posts wins in mPDAC, mCRC and NSCLC
Vanda puts anxiety drug’s development on ice after Phase III fail
Spinogenix adds Phase IIb autism study to CLARITY basket trial
Pilatus doses first patient in Phase I PLT012 trial for HCC
Arrowhead’s Alzheimer’s disease drug reduces tau in Phase I/IIa trial
MHRA homes in on personalised healthcare and tech in new 2030 strategy
